The EHMT2 Knockout HAP1 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population targeting the EHMT2 gene in the HAP1 near-haploid human cell line. This pool of edited cells offers a genetically heterogeneous loss-of-function model for studying the cellular roles of the euchromatic histone-lysine N-methyltransferase 2 (EHMT2, also known as G9a). The population-based knockout format avoids clonal artifacts and preserves biological variation, making it suitable for functional genomics and pooled screening applications.
The HAP1 cell line is a human near-haploid cell type with fibroblast-like morphology, originally derived from a male patient with chronic myeloid leukemia. Its haploid karyotype simplifies genome engineering and enables efficient CRISPR/Cas9-mediated gene disruption, as only one allele needs targeting. This characteristic, combined with robust growth and amenability to high-throughput assays, establishes HAP1 as a workhorse model for genetic interaction studies, drug screening, and loss-of-function analyses in epigenetic research.
EHMT2 encodes a histone methyltransferase that catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/2), key marks of facultative heterochromatin. It functions in a complex with WIZ and the related methyltransferase EHMT1 (GLP), and is regulated by upstream kinases CDK1 and AKT, as well as PRMT5. H3K9me2 serves as a docking site for HP1 proteins, which compact chromatin and silence transcription. EHMT2 also interacts with corepressors CDYL, ATF7IP, and DNMT3A, integrating histone and DNA methylation. Collectively, EHMT2 orchestrates repression of genes controlling cell cycle, differentiation, and tumor suppression.
Disruption of EHMT2 in the HAP1 near-haploid background provides a powerful system to dissect the role of H3K9 methylation in chromatin regulation. The polyclonal knockout population globally reduces H3K9 dimethylation levels, which can be monitored by western blotting or immunofluorescence, and leads to derepression of EHMT2 target genes, detectable by RT-qPCR or RNA-seq. Because HAP1 cells retain near-haploidy, the phenotypic consequences of EHMT2 loss??such as effects on proliferation, DNA damage response, or differentiation??can be attributed directly to the gene disruption without the confounding influence of a second allele. This model is particularly valuable for validating chemical inhibitors of EHMT2 and for mapping genetic interactions with other chromatin modifiers like SUV39H1 or SETDB1 in an isogenic setting.
This polyclonal EHMT2 knockout product is suitable for a broad range of research applications in epigenetics and cancer biology. Researchers can employ it in chromatin immunoprecipitation (ChIP)-qPCR or ChIP-seq to profile H3K9me2 occupancy at specific genomic loci, or perform RNA-seq to characterize transcriptome-wide changes upon loss of EHMT2. It serves as an ideal negative control for drug-target validation studies, enabling dose-response assays to assess the specificity of EHMT2 inhibitors. Additional applications include genetic interaction screens using CRISPRi or CRISPRa libraries, cell proliferation and migration assays, and biochemical studies of EHMT2-containing complexes. For further information or to discuss custom uses, please contact Ascent Research.
